The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation models.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innov ...
Pharmaceutical Technology on MSN
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up
Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.
Zacks Investment Research on MSN
Novavax grants license for use of Matrix-M adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback